These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24418752)

  • 1. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
    Kraus M; Müller-Ide H; Rückrich T; Bader J; Overkleeft H; Driessen C
    Leuk Res; 2014 Mar; 38(3):383-92. PubMed ID: 24418752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.
    Kraus M; Bader J; Overkleeft H; Driessen C
    Blood Cancer J; 2013 Mar; 3(3):e103. PubMed ID: 23454896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
    Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
    BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
    Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
    Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function.
    Piccinini M; Rinaudo MT; Anselmino A; Buccinnà B; Ramondetti C; Dematteis A; Ricotti E; Palmisano L; Mostert M; Tovo PA
    Antivir Ther; 2005; 10(2):215-23. PubMed ID: 15865215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
    Besse A; Sedlarikova L; Buechler L; Kraus M; Yang CH; Strakova N; Soucek K; Navratil J; Svoboda M; Welm AL; Joerger M; Driessen C; Besse L
    Br J Cancer; 2024 Sep; 131(5):918-930. PubMed ID: 38969867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.
    Pajonk F; Himmelsbach J; Riess K; Sommer A; McBride WH
    Cancer Res; 2002 Sep; 62(18):5230-5. PubMed ID: 12234989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.
    Kim JY; Park YJ; Lee BM; Yoon S
    Anticancer Res; 2019 Jul; 39(7):3757-3765. PubMed ID: 31262902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
    Schütt M; Zhou J; Meier M; Klein HH
    J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
    Vernochet C; Azoulay S; Duval D; Guedj R; Ailhaud G; Dani C
    AIDS; 2003 Oct; 17(15):2177-80. PubMed ID: 14523274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells.
    Bode H; Lenzner L; Kraemer OH; Kroesen AJ; Bendfeldt K; Schulzke JD; Fromm M; Stoltenburg-Didinger G; Zeitz M; Ullrich R
    Antivir Ther; 2005; 10(5):645-55. PubMed ID: 16152758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.
    Jiang W; Mikochik PJ; Ra JH; Lei H; Flaherty KT; Winkler JD; Spitz FR
    Cancer Res; 2007 Feb; 67(3):1221-7. PubMed ID: 17283158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
    Gills JJ; Lopiccolo J; Tsurutani J; Shoemaker RH; Best CJ; Abu-Asab MS; Borojerdi J; Warfel NA; Gardner ER; Danish M; Hollander MC; Kawabata S; Tsokos M; Figg WD; Steeg PS; Dennis PA
    Clin Cancer Res; 2007 Sep; 13(17):5183-94. PubMed ID: 17785575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
    Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
    Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.
    Bruning A; Vogel M; Mylonas I; Friese K; Burges A
    Curr Cancer Drug Targets; 2011 Sep; 11(7):799-809. PubMed ID: 21762082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
    Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
    Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
    Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
    Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.